Hugo de Luca Corrêa1, André Bonadias Gadelha2,3, Baruch Vainshelboim4, Maurílio Tiradentes Dutra5,6, João B Ferreira-Júnior7, Lysleine Alves Deus8, Rodrigo Vanerson Passos Neves8, Andrea Lucena Reis8, Thaís Branquinho de Araújo8, Carmen Tzanno-Martins9, Fernanda Silveira Tavares10, Rosângela Vieira Andrade11, Thiago Dos Santos Rosa8. 1. Graduate Program of Physical Education, Catholic University of Brasilia, UCB, EPTC, QS07, LT1 s/n. Bloco G Sala 119, Águas Claras, Taguatinga, Brasília, DF, 72030-170, Brazil. hugo.efucb@gmail.com. 2. Serviço de Preparação Física/COSAU/DIGEP/SA/SG/Presidência da República, Zona Cívico-Administrativa, Brasília, DF, 70150-900, Brazil. 3. Seção de Educação Física, Colégio Militar de Brasília, Asa Norte, Brasília, DF, Brasil. 4. Cardiovascular and Metabolic Disease Research Institute, Mountain View, CA, USA. 5. Federal Institute of Education, Science and Technology of Brasilia, College of Physical Education, Brasília, Brazil. 6. College of Physical Education, University of Brasília, Brasília, DF, Brazil. 7. Federal Institute of Sudeste of Minas Gerais, Campus Rio Pomba, Rio Pomba, MG, Brazil. 8. Graduate Program of Physical Education, Catholic University of Brasilia, UCB, EPTC, QS07, LT1 s/n. Bloco G Sala 119, Águas Claras, Taguatinga, Brasília, DF, 72030-170, Brazil. 9. HDC RenalClass, São Paulo, Brazil. 10. Department of Medicine, Catholic University of Brasilia, Brasília, DF, Brazil. 11. Graduate Program of Genomic Sciences and Biotechnology, Catholic University of Brasilia, Brasília, DF, Brazil.
Abstract
PURPOSE: To investigate the association between sarcopenia with the number of all-cause mortality, hospitalizations, and cardiovascular diseases in patients with end-stage renal disease (ESRD). METHODS: 247 patients with ESRD (women, n = 97) (66.6 ± 3.53 years) participated in this study. At baseline, all participants were measured with dual-energy X-ray absorptiometry and handgrip dynamometer and were prospectively followed up for 5 years. The European Working Group on Sarcopenia in Older People guidelines were utilized for Sarcopenia determination. Cox proportional hazard analysis adjusted for established risk factors was used to quantify the risk between Sarcopenia and all-cause mortality. RESULTS: Sixty-five participants (26%) were determined to have Sarcopenia at baseline and 38 (15%) have died during the follow-up. At baseline, Participants with Sarcopenia had lower body mass index and fat-free mass index. Moreover, through the 5-year follow-up, sarcopenic patients had higher number of cardiovascular disease (56.9% vs. 12.6%) and hospitalizations (93.8% vs. 49.5%) (all P < 0.0001). Sarcopenia was associated with significantly higher risk of mortality, [Hazard ratio = 3.3, (95% CI: 1.6-6.9), P = 0.001]. CONCLUSION: Sarcopenia may be a risk factor for hospitalizations, cardiovascular diseases, and all-cause mortality in patients with ESRD. These results provide support of the relevance in assessing sarcopenia in the clinical practice of chronic kidney disease and how muscle mass and strength may negatively impact the daily life of ESRD patients undergoing hemodialysis. Greater efforts at preventing muscle wasting and malfunctioning are needed through the worldwide healthcare system.
PURPOSE: To investigate the association between sarcopenia with the number of all-cause mortality, hospitalizations, and cardiovascular diseases in patients with end-stage renal disease (ESRD). METHODS: 247 patients with ESRD (women, n = 97) (66.6 ± 3.53 years) participated in this study. At baseline, all participants were measured with dual-energy X-ray absorptiometry and handgrip dynamometer and were prospectively followed up for 5 years. The European Working Group on Sarcopenia in Older People guidelines were utilized for Sarcopenia determination. Cox proportional hazard analysis adjusted for established risk factors was used to quantify the risk between Sarcopenia and all-cause mortality. RESULTS: Sixty-five participants (26%) were determined to have Sarcopenia at baseline and 38 (15%) have died during the follow-up. At baseline, Participants with Sarcopenia had lower body mass index and fat-free mass index. Moreover, through the 5-year follow-up, sarcopenic patients had higher number of cardiovascular disease (56.9% vs. 12.6%) and hospitalizations (93.8% vs. 49.5%) (all P < 0.0001). Sarcopenia was associated with significantly higher risk of mortality, [Hazard ratio = 3.3, (95% CI: 1.6-6.9), P = 0.001]. CONCLUSION: Sarcopenia may be a risk factor for hospitalizations, cardiovascular diseases, and all-cause mortality in patients with ESRD. These results provide support of the relevance in assessing sarcopenia in the clinical practice of chronic kidney disease and how muscle mass and strength may negatively impact the daily life of ESRD patients undergoing hemodialysis. Greater efforts at preventing muscle wasting and malfunctioning are needed through the worldwide healthcare system.
Authors: Raíssa A Pereira; Antonio C Cordeiro; Carla M Avesani; Juan J Carrero; Bengt Lindholm; Fernanda C Amparo; Celso Amodeo; Lilian Cuppari; Maria A Kamimura Journal: Nephrol Dial Transplant Date: 2015-05-21 Impact factor: 5.992
Authors: Marije H Kallenberg; Hilda A Kleinveld; Friedo W Dekker; Barbara C van Munster; Ton J Rabelink; Marjolijn van Buren; Simon P Mooijaart Journal: Clin J Am Soc Nephrol Date: 2016-06-24 Impact factor: 8.237
Authors: Thomas J Wilkinson; Joanne Miksza; Thomas Yates; Courtney J Lightfoot; Luke A Baker; Emma L Watson; Francesco Zaccardi; Alice C Smith Journal: J Cachexia Sarcopenia Muscle Date: 2021-05-05 Impact factor: 12.063
Authors: Susan L Ziolkowski; Jin Long; Joshua F Baker; Glenn M Chertow; Mary B Leonard Journal: J Cachexia Sarcopenia Muscle Date: 2019-02-19 Impact factor: 12.910
Authors: Juergen Bauer; John E Morley; Annemie M W J Schols; Luigi Ferrucci; Alfonso J Cruz-Jentoft; Elsa Dent; Vickie E Baracos; Jeffrey A Crawford; Wolfram Doehner; Steven B Heymsfield; Aminah Jatoi; Kamyar Kalantar-Zadeh; Mitja Lainscak; Francesco Landi; Alessandro Laviano; Michelangelo Mancuso; Maurizio Muscaritoli; Carla M Prado; Florian Strasser; Stephan von Haehling; Andrew J S Coats; Stefan D Anker Journal: J Cachexia Sarcopenia Muscle Date: 2019-09-15 Impact factor: 12.910